» Articles » PMID: 37291502

Incidence and Risk Factors of Pneumococcal Pneumonia in Adults: a Population-based Study

Abstract

Background: Infection caused by Streptococcus pneumoniae, mainly invasive pneumococcal disease (IPD) and pneumococcal pneumonia (PP), are a major public health problem worldwide. This study investigated population-based incidence and risk of PP among Catalonian persons ≥ 50 years-old with and without specific underlying conditions/comorbidities, examining the influence of single and multi-comorbidities in the risk of suffering PP.

Methods: Population-based cohort study involving 2,059,645 persons ≥ 50 years-old in Catalonia, Spain, who were retrospectively followed between 01/01/2017-31/12/2018. The Catalonian information system for development of research in primary care (SIDIAP) was used to establish baseline characteristics of the cohort (comorbidities/underlying conditions), and PP cases were collected from discharge codes (ICD-10: J13) of the 68 referral Catalonian hospitals.

Results: Global incidence rate (IR) was 90.7 PP cases per 100,000 person-years, with a 7.6% (272/3592) case-fatality rate (CFR). Maximum IRs emerged among persons with history of previous IPD or all-cause pneumonia, followed by haematological neoplasia (475.0), HIV-infection (423.7), renal disease (384.9), chronic respiratory disease (314.7), liver disease (232.5), heart disease (221.4), alcoholism (204.8), solid cancer (186.2) and diabetes (159.6). IRs were 42.1, 89.9, 201.1, 350.9, 594.3 and 761.2 in persons with 0, 1, 2, 3, 4 and ≥ 5 comorbidities, respectively. In multivariable analyses, HIV-infection (hazard ratio [HR]: 5.16; 95% CI: 3.57-7.46), prior all-cause pneumonia (HR: 3.96; 95% CI: 3.45-4.55), haematological neoplasia (HR: 2.71; 95% CI: 2.06-3.57), chronic respiratory disease (HR: 2.66; 95% CI: 2.47-2.86) and prior IPD (HR: 2.56; 95% CI: 2.03-3.24) were major predictors for PP.

Conclusion: Apart of increasing age and immunocompromising conditions (classically recognised as high-risk conditions), history of prior IPD/pneumonia, presence of chronic pulmonary/respiratory disease and/or co-existing multi-comorbidity (i.e., two or more underlying conditions) are major risk factors for PP in adults, with an excess risk near to immunocompromised subjects. Redefining risk categories for PP, including all the above-mentioned conditions into the high-risk category, could be necessary to improve prevention strategies in middle-aged and older adults.

Citing Articles

A nomogram for predicting mortality risk in geriatric patients with hip fractures complicated by pneumonia: A multicenter study.

Zhang K, Li X, Xiao Y, Zhou C, Liu Y, Zhen F SAGE Open Med. 2025; 13:20503121251319168.

PMID: 39925961 PMC: 11806483. DOI: 10.1177/20503121251319168.


Diagnostic Approach to Pneumonia in Immunocompromised Hosts.

Ullah N, Fusco L, Ametrano L, Bartalucci C, Giacobbe D, Vena A J Clin Med. 2025; 14(2).

PMID: 39860395 PMC: 11765643. DOI: 10.3390/jcm14020389.


Cost-Effectiveness of the Pneumococcal Vaccine in the Adult Population: A Systematic Review.

Vo N, Pham H, Bui U, Ho H, Bui T Healthcare (Basel). 2024; 12(23).

PMID: 39685112 PMC: 11641157. DOI: 10.3390/healthcare12232490.


Risk factors for SARS-CoV-2 pneumonia among renal transplant recipients in Omicron pandemic-a prospective cohort study.

Zhang S, Ding X, Geng C, Zhang H Virol J. 2024; 21(1):315.

PMID: 39633492 PMC: 11619572. DOI: 10.1186/s12985-024-02591-9.


Incidence of Invasive and Noninvasive Pneumococcal Pneumonia Hospitalizations in People Aged ≥50 Years: Assessing Variability Across Denmark and Spain.

Lopez-Lacort M, Amini M, Emborg H, Nielsen J, McDonald S, Valentiner-Branth P J Infect Dis. 2024; 230(3):e559-e567.

PMID: 38459772 PMC: 11420809. DOI: 10.1093/infdis/jiae088.


References
1.
Hurley D, Griffin C, Young M, Scott D, Pride M, Scully I . Safety, Tolerability, and Immunogenicity of a 20-Valent Pneumococcal Conjugate Vaccine (PCV20) in Adults 60 to 64 Years of Age. Clin Infect Dis. 2020; 73(7):e1489-e1497. PMC: 8492133. DOI: 10.1093/cid/ciaa1045. View

2.
Leidner A, Murthy N, Chesson H, Biggerstaff M, Stoecker C, Harris A . Cost-effectiveness of adult vaccinations: A systematic review. Vaccine. 2018; 37(2):226-234. PMC: 6545890. DOI: 10.1016/j.vaccine.2018.11.056. View

3.
Niederman M, Folaranmi T, Buchwald U, Musey L, Cripps A, Johnson K . Efficacy and effectiveness of a 23-valent polysaccharide vaccine against invasive and noninvasive pneumococcal disease and related outcomes: a review of available evidence. Expert Rev Vaccines. 2021; 20(3):243-256. DOI: 10.1080/14760584.2021.1880328. View

4.
Treskova M, Scholz S, Kuhlmann A . Cost Effectiveness of Elderly Pneumococcal Vaccination in Presence of Higher-Valent Pneumococcal Conjugate Childhood Vaccination: Systematic Literature Review with Focus on Methods and Assumptions. Pharmacoeconomics. 2019; 37(9):1093-1127. DOI: 10.1007/s40273-019-00805-5. View

5.
Vila-Corcoles A, Ochoa-Gondar O, de Diego-Cabanes C, Satue-Gracia E, Torras-Vives V, Forcadell-Peris M . Evaluating clinical effectiveness and impact of anti-pneumococcal vaccination in adults after universal childhood PCV13 implementation in Catalonia, 2017-2018. Vaccine X. 2023; 13:100264. PMC: 9926188. DOI: 10.1016/j.jvacx.2023.100264. View